HOOK (HOOKIPA Pharma) Retained Earnings: $-429.98 Mil (As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma Retained Earnings?

HOOKIPA Pharma HOOK 50 Retained Earnings is $-429.98 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. HOOKIPA Pharma's retained earnings for the quarter that ended in Jun. 2025 was $-429.98 Mil.

HOOKIPA Pharma's quarterly retained earnings declined from Dec. 2024 ($-412.76 Mil) to Mar. 2025 ($-428.19 Mil) and declined from Mar. 2025 ($-428.19 Mil) to Jun. 2025 ($-429.98 Mil).

HOOKIPA Pharma's annual retained earnings declined from Dec. 2022 ($-287.68 Mil) to Dec. 2023 ($-369.26 Mil) and declined from Dec. 2023 ($-369.26 Mil) to Dec. 2024 ($-412.76 Mil).


HOOKIPA Pharma  (OTCPK:HOOK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


HOOKIPA Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Retained Earnings Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -147.10 -222.77 -287.68 -369.26 -412.76

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -373.97 -387.81 -412.76 -428.19 -429.98
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-429.98 Mil mean?
HOOKIPA Pharma (HOOK) has a Retained Earnings of $-429.98 Mil as of Jun. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Retained Earnings too high?
HOOKIPA Pharma's current Retained Earnings is $-429.98 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Retained Earnings compare to COCP and LNAI?
HOOKIPA Pharma's Retained Earnings of $-429.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Retained Earnings is $-429.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Retained Earnings of $-429.98 Mil. The current Retained Earnings is $-429.98 Mil. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Retained Earnings is $-429.98 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price